title: The effect of ranitidine on cellular immunity in patients with multiple myeloma.
abstract: Multiple myeloma is characterized by an increased susceptibility to infections and to other malignancies. In a double-blind, placebo-controlled study the potential impact of immunomodulation by ranitidine was studied in 20 patients with multiple myeloma. Three patients were untreated, while 17 after previous cytotoxic therapy were in a stable phase of their disease. All were without clinical signs of infections and at that time had not been treated with other immunomodulating agents. The patients were randomized to oral ranitidine 300 mg twice a day for 21 days or placebo, and several immunological parameters related to multiple myeloma were studied. The blood monocyte chemotactic response was improved in patients treated with ranitidine, and superoxide anion production increased from 2.02 nmol/min to 3.86 nmol/min (median values), while it was unchanged in patients given placebo (2.19-2.25 nmol/min) (P less than 0.005 between groups). Among ranitidine-treated patients spontaneous NK cell activity was unchanged, while in vitro interleukin-2- and interferon-alpha-stimulated NK cell activity decreased (P less than 0.03, respectively). As production of oxygen radicals constitutes an important mechanism of monocyte killing activity against microorganisms and probably against malignant cells, it is suggested that ranitidine may be of beneficial impact in the treatment of multiple myeloma.
authors.affiliation: Department of Surgical Gastroenterology, Hvidovre University Hospital, Denmark.
authors.forename: H J
authors.initials: HJ
authors.lastname: Nielsen
authors.forename: H
authors.initials: H
authors.lastname: Nielsen
authors.forename: F
authors.initials: F
authors.lastname: Moesgaard
authors.forename: N
authors.initials: N
authors.lastname: Tvede
authors.forename: K
authors.initials: K
authors.lastname: Klarlund
authors.forename: B
authors.initials: B
authors.lastname: Mansa
authors.forename: A
authors.initials: A
authors.lastname: Drivsholm
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007136:Immunoglobulins / Q000378:metabolism; D007958:Leukocyte Count / Q000187:drug effects; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000502:physiology; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology*; D010266:Paraproteins / Q000378:metabolism; D011899:Ranitidine / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000276:Adjuvants, Immunologic; D007136:Immunoglobulins; D010266:Paraproteins; D011899:Ranitidine